Zanolimumab: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
CheMoBot (talk | contribs)
Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref') per Chem/Drugbox validation (report [[Wikipedia talk:WikiProject_Ph
CheMoBot (talk | contribs)
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[Wikipedia:WikiProject Chemicals/Chembox validation|Chem/Drug
Line 1: Line 1:
{{drugbox
{{drugbox
| UNII_Ref = {{fdacite|correct|FDA}}
| Verifiedfields = changed
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = HG3L8885M0
| UNII = HG3L8885M0
| verifiedrevid = 409117208
| verifiedrevid = 437178755
| type = mab
| type = mab
| image =
| image =
Line 13: Line 12:
| ATC_suffix =
| ATC_suffix =
| PubChem =
| PubChem =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| DrugBank =
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG_Ref = {{keggcite|correct|kegg}}

Revision as of 02:22, 14 August 2011

Zanolimumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCD4
Clinical data
ATC code
  • none
Identifiers
CAS Number
UNII
KEGG
Chemical and physical data
Molar mass147 kDa
  (verify)

Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma [2], cutaneous and peripheral T-cell lymphoma.[3][4]

References

  1. ^ Genmab initiates Phase II Study with HuMax-CD4
  2. ^ http://www.tenxbiopharma.com/development.shtml
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
  4. ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov